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The combination of human genetics, animal models, and induced pluripotent stem cells is likely 
to revolutionize our understanding of neuropsychiatric disorders, leading to new therapies and 
insights into how the normal human brain works. This is the territory I would explore if I were 
starting my research career today.I trained as a clinical neurologist before 
becoming a basic scientist. In my 34 
years as a practicing scientist, I did 
research in immunology, cell biology, 
and developmental neurobiology before 
retiring in 2002 (Raff, 2006). Despite 9 
years of medical training, I chose to work 
exclusively on mice and rats and only 
rarely on the biology of disease.
If I were starting a research career 
today, however, I would follow a very 
different path. One reason is that I now 
have a 7-year-old grandson with autism, 
which has greatly stimulated my inter-
est in autism spectrum disorders (ASDs) 
and other neuropsychiatric conditions. 
Another is that technological advances 
have made it possible to study the brain 
in ways that were unimaginable even a 
few years ago.
I would begin with mutations known 
to have an important role in some indi-
viduals with a major neuropsychiatric 
disease such as autism, schizophrenia, 
or bipolar disorder. Armed, for example, 
with a mutation that can cause or greatly 
increase the risk of bipolar disorder in 
some individuals, I could well be on a 
tractable pathway to understanding nor-
mal human mood control, which is dra-
matically disturbed in bipolar individuals 
and is still poorly understood.
There are other good reasons for 
studying neuropsychiatric disorders. 
These conditions are an enormous bur-
den to society, in terms of both eco-
nomic cost and human suffering: they 
are responsible for more than 40% of all 
years lived with disability in North Amer-
ica and Europe (Hyman, 2008). They are 
still largely mysterious, which is mainly 
why there has been so little advance 
in their medical treatment in the past 
60 years or so. Nonetheless, there are grounds for optimism. In most neurode-
generative diseases such as Alzheimer’s 
and Parkinson’s diseases and amyo-
trophic lateral sclerosis (ALS), nerve cells 
progressively degenerate and die, but, 
in the neuropsychiatric disorders, nerve 
cells generally do not degenerate or 
die. Moreover, recent studies of mouse 
models of genetic forms of neuropsychi-
atric disorders suggest that many of the 
behavioral and physiological abnormali-
ties reflect reversible functional defects 
in the adult brain, rather than irreversible 
structural defects (Ehninger et al., 2008). 
There is now a pressing need to discover 
what these functional neurobiological 
defects are.
Rapid advances in analyzing DNA in 
large numbers of affected individuals 
have made it possible to identify genetic 
contributions to some of the major neu-
ropsychiatric disorders (Hyman, 2008). 
The genetic contributions are mainly 
of two types: (1) common genetic vari-
ants (polymorphisms), each of which 
has a small effect, generally increasing 
the risk of developing the disorder less 
than 2-fold, and (2) rare mutations that 
have a large effect on risk and, in some 
cases, can be causative. As shown for a 
number of neurodegenerative diseases, 
even when a large-effect genetic abnor-
mality occurs in only a small subset of 
individuals with the disease, it can allow 
the production of powerful animal mod-
els for analyzing the disease process. 
Animal models of Alzheimer’s and Par-
kinson’s diseases and ALS, for example, 
have revolutionized the study of these 
diseases, and they have depended on 
the initial identification of large-effect 
mutations in uncommon familial forms 
of the diseases (for example, Rosen et 
al., 1993).Cell 139, DAn increasing number of large-effect 
mutations are now being identified in 
some of the major neuropsychiatric disor-
ders, and there are excellent mouse mod-
els for a number of them. An especially 
informative example is Rett syndrome, in 
which the mutant gene is MECP2 on the 
X chromosome (Chahrour and Zoghbi, 
2007). The gene encodes a protein that 
binds to methylated cytosines in DNA 
and is thought to regulate the expres-
sion of many genes. Whereas boys with 
an MECP2 mutation die early, girls (who 
have one good copy of MECP2) develop 
normally for a year or two and then rapidly 
regress: they lose speech and develop 
cognitive and autonomic defects, ataxia, 
tremor, and irregular breathing; eventually, 
their condition stabilizes or even improves 
somewhat, and they usually live a normal 
life span. Many girls with Rett syndrome 
develop autistic features, in which case it 
is considered a “syndromic” form of ASD, 
as the autism is only part of a more com-
plex neurological disorder. Mouse mod-
els of Rett syndrome closely resemble 
the human condition: whereas male mice 
develop neurological signs at 6 weeks 
and die at around 10 weeks, females 
develop normally for 5–10 months and 
then regress. The female mice develop 
similar neurological signs to those seen in 
girls with Rett syndrome, and like them, 
the female mice eventually stabilize and 
live a normal life span.
Many children with ASD also regress 
toward the end of their second year. 
The mechanism of regression in both 
Rett syndrome and other ASDs remains 
a mystery. Does it reflect a failure to 
maintain or strengthen some specific 
neuronal connections, for example? The 
Rett syndrome mouse seems an ideal 
model to find out.ecember 24, 2009 ©2009 Elsevier Inc. 1209
Adrian Bird and colleagues investi-
gated a different question in Rett mice. 
They made a Rett mouse in which they 
could reverse the genetic defect in the 
adult animal (Guy et al., 2007). They 
replaced the normal MECP2 gene with 
one containing an excisable stop sig-
nal, so the MeCP2 protein could not be 
made until the stop signal was excised. 
In the same mouse, they expressed an 
inducible transgene that encodes a DNA 
recombinase enzyme (Cre recombinase) 
that could be activated by the estrogen 
analog tamoxifen; the activated enzyme 
removes the stop signal, allowing the 
MeCP2 protein to be made. Remark-
ably, treatment of severely disabled 
adult mice with tamoxifen reversed 
most of the neurological and physi-
ological deficits within a few weeks. As 
Rett syndrome has been considered 
a developmental brain disorder, this 
result was entirely unexpected. Sub-
sequently, a number of other genetic 
mouse models of neuropsychiatric dis-
orders have been partially reversed by 
drug treatment of adult mice (Ehninger 
et al., 2008). These are very encourag-
ing results, with promising implications 
for the treatment of these devastating 
disorders in humans. Interestingly, the 
first report of the partial reversal of a 
genetic brain disorder in a mouse model 
involved Huntington’s disease, a classi-
cal neurodegenerative disorder in which 
a mutant form of the protein huntingtin 
accumulates in neurons. Turning off 
the mutant huntingtin transgene at 18 
weeks in an inducible mouse model of 
the disease led to the disappearance of 
the mutant protein and a partial reversal 
of both the neuropathology and motor 
abnormalities (Yamamoto et al., 2000).
All brain functions depend on synaptic 
connections between nerve cells, and 
there is increasing evidence that defects 
in these connections may be responsible 
for some of the major neuropsychiatric 
disorders. Some large-effect mutations 
in genes that encode proteins that func-
tion only at synapses, for example, can 
predispose to ASDs (Jamain et al., 2003). 
Many hundreds of different proteins 
operate at synapses, and it is possible 
that mutations and polymorphisms in a 
number of the genes that encode these 
proteins can increase the risk of ASDs. 
So far, none of the large-effect muta-1210 Cell 139, December 24, 2009 ©2009 Etions found to predispose to ASDs are 
specific for ASDs; the same mutations 
can be associated with cognitive impair-
ment, seizures, or other neuropsychiat-
ric disorders (Abrahams and Geschwind, 
2008).
How can we test the possibility that 
a synaptic defect is responsible for a 
particular neuropsychiatric disorder 
in humans? A direct way would be to 
study synaptic behavior in the brains 
of affected individuals, but this cannot 
yet be done in the intact human brain. 
A possible alternative route involves the 
production of induced pluripotent stem 
(iPS) cells from adult cells derived from 
individuals with these disorders and then 
inducing these iPS cells to form neurons 
and synapses. It is this strategy that 
I would pursue if I were starting out in 
science today, but I would start with a 
mouse model and iPS cells derived from 
it, before turning to human iPS cells.
Thanks to the pioneering efforts of 
Shinya Yamanaka, it is now possible to 
produce iPS cells from mouse or human 
somatic cells by transiently expressing 
several transgenes that encode spe-
cific transcription factors (Yamanaka, 
2009). Some of the transfected cells 
can be isolated as cell lines that closely 
resemble embryonic stem (ES) cells: 
they can proliferate indefinitely in culture 
and give rise to almost any cell type nor-
mally found in the body. They can form 
nerve cells, for example, which in turn 
can form synapses—either in culture or 
after transplantation into an embryonic 
mouse brain.
I would aim for a relatively simple 
model. One possibility would be to 
start with a gene that encodes a protein 
thought to operate exclusively at syn-
apses and where mutations can have a 
major role in some individuals with an 
ASD. Neuroligin 4 (NLGN4), for example, 
encodes a postsynaptic cell adhesion 
protein (Sudhof, 2008), and large-effect 
mutations in the gene have been found 
in a small number of ASD individuals 
(Jamain et al., 2003), as well as in some 
individuals with cognitive impairment 
without an ASD (Laumonnier et al., 2004). 
An NLGN4-deficient mouse has highly 
selective defects in “social” interactions 
and vocalization, resembling some of the 
core defects in individuals with an ASD 
(Jamain et al., 2008).lsevier Inc.First, I would try to determine which 
parts of the brain and which cell types 
are responsible for the behavioral phe-
notype in the NLGN4-deficient mouse: I 
would either inactivate the NLGN4 gene 
in specific brain regions or specific cell 
types or try to rescue the phenotype of 
NLGN4-deficient mice by putting the 
wild-type NLGN4 gene back into specific 
brain regions or specific cell types. Once 
I had identified the relevant brain regions 
and cell types, I would take advantage of 
the powerful techniques for analyzing the 
mouse brain, either intact or in slices, to 
look in these regions for possible defects 
in synapse formation, maturation, func-
tion, plasticity, and homeostasis, as well 
as for defects in neural circuits. I would 
also try to reproduce any identified 
defects in dissociated cell cultures pre-
pared from these regions. Crucially, to 
inform my eventual studies using human 
iPS cells, I would make iPS cells from the 
mutant mice and try to induce them to 
produce the appropriate types of cells 
and synaptic connections, either in cul-
ture or in mouse embryos, in an attempt 
to reproduce the identified abnormali-
ties. The remarkable finding that mouse 
ES cells in culture can produce the multi-
ple types of pyramidal neurons normally 
found in the mouse cerebral cortex and 
produce them in the normal develop-
mental sequence (Gaspard et al., 2008) 
increases my confidence that this iPS 
cell strategy will work.
If I managed to achieve all of this, which 
could well take years, I would test candi-
date drugs to see if any could correct the 
defects in mutant brain slices or cultures. 
If none worked, I would try to devise a 
robust cell culture system, derived from 
either mutant brain or mutant iPS cells, 
to screen for new drug candidates. I 
would test any drug found to be effective 
to see if it could correct the behavioral 
abnormalities in the mutant mice, which 
would provide strong evidence that the 
defects identified in vitro are responsible 
for the behavioral defects.
Now, finally, I would be ready to 
make iPS cells from ASD individuals 
carrying the same or a similar muta-
tion. The results from the mouse exper-
iments would inform these studies on 
human cells by suggesting the types 
of neural cells (neurons, glia, or both), 
synapses, and circuits I would need to 
produce, as well as how to produce 
them. As in the mouse experiments, I 
would analyze the cells in culture and 
after transplantation into fetal mouse 
brain. If I succeeded in reproducing 
the defects demonstrated earlier using 
cells derived from mutant mouse iPS 
cells, I would test the drugs that cor-
rected the mouse cell defects to see if 
they also corrected the defects found 
in the human cells; if not, I would 
repeat the drug screen on the human 
cells. Any drugs found to be effective 
in vitro could serve as starting mate-
rial for developing drugs to test in the 
mutant ASD individuals. If this strat-
egy worked, it would not only be great 
news for the ASD individuals, it would 
also provide strong evidence that the 
identified neural defects are an impor-
tant contributor to the ASD behavioral 
phenotype. (Note that this strategy 
does not entail the transplantation 
into humans of either iPS cells or cells 
derived from iPS cells, and it therefore 
avoids any safety concerns about the 
expression of transgenes or the use of 
pluripotent stem cells.)
Of course, long-term strategies, such 
as the one outlined here, rarely work 
out as planned. It is likely that unex-
pected results would suggest alterna-
tive interpretations, and new technolo-
gies would allow better experimental 
routes forward; brain imaging studies in 
mutant mice and humans, for example, 
might help to identify the relevant brain 
regions. An important concern is that 
differences between the mouse brain 
and human brain might invalidate the 
mouse models, which could doom the 
strategy. Moreover, defects in synaptic 
connections may not be as important as 
I suspect they are in at least some of the major neuropsychiatric disorders, and it 
may be very difficult to distinguish pri-
mary abnormalities from those that are 
secondary and compensatory; this strat-
egy, however, may help to resolve these 
important issues.
As DNA sequencing becomes faster 
and cheaper, new large-effect muta-
tions will increasingly be discovered in 
the neuropsychiatric disorders, provid-
ing new starting points for the strategy. 
On the other hand, there is no reason to 
wait for new genes, as there are already 
enough to get started, and some labo-
ratories are well along this pathway in 
analyzing these genes in mouse models 
(for example, Fyffe et al., 2008). There 
is little doubt that human iPS cells will 
prove to be invaluable in the search 
for the molecular and cellular bases of 
these disorders, but I suspect that, in 
most cases, a great deal of hard work 
on animal models and mouse iPS cells 
will first be necessary to guide the 
human studies.
The combination of human genetics, 
animal models, and iPS cells promises 
to revolutionize our understanding of the 
major neuropsychiatric disorders, as it 
already has done for many neurodegen-
erative diseases. The payoff here could 
be greater than it has been so far for the 
neurodegenerative diseases, both for 
the development of new effective thera-
pies and for understanding the work-
ings of the normal human brain, which is 
arguably the biggest challenge for biolo-
gists today. I could not resist being part 
of such a worthy adventure.
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